ACB vs. CDXC, BTMD, MDWD, FTLF, MNMD, USNA, CGC, CRON, AMRN, and ADCT
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include ChromaDex (CDXC), biote (BTMD), MediWound (MDWD), FitLife Brands (FTLF), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), Canopy Growth (CGC), Cronos Group (CRON), Amarin (AMRN), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector.
Aurora Cannabis (NASDAQ:ACB) and ChromaDex (NASDAQ:CDXC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings, community ranking and profitability.
ChromaDex has a net margin of -4.24% compared to Aurora Cannabis' net margin of -48.82%. ChromaDex's return on equity of -12.61% beat Aurora Cannabis' return on equity.
Aurora Cannabis has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.
ChromaDex has lower revenue, but higher earnings than Aurora Cannabis. ChromaDex is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
ChromaDex received 152 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 63.99% of users gave ChromaDex an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
ChromaDex has a consensus target price of $6.00, indicating a potential upside of 81.82%. Given ChromaDex's higher probable upside, analysts plainly believe ChromaDex is more favorable than Aurora Cannabis.
In the previous week, Aurora Cannabis had 2 more articles in the media than ChromaDex. MarketBeat recorded 12 mentions for Aurora Cannabis and 10 mentions for ChromaDex. Aurora Cannabis' average media sentiment score of 0.80 beat ChromaDex's score of -0.39 indicating that Aurora Cannabis is being referred to more favorably in the media.
47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 15.4% of ChromaDex shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 10.6% of ChromaDex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
ChromaDex beats Aurora Cannabis on 11 of the 16 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
